UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy — PiB ADC  

Alzheimer Disease Clinical Trial

Official title: UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

Status Recruiting

Clinical Trial Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

Clinical Trial Description

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB-ADC cohort. The amount and distribution of [C-11]PiB in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study. As a secondary aim, the investigators will assess the ability of the early flow frames from [C-11]PiB-PET and brain volumetric measurements with MRI to serve as a marker of neuronal injury and to predict cognitive status in conjunction with the amyloid-PET results. ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT03503331
• Study type: Interventional
• Source: University of Alabama at Birmingham
• Contact: April Riddle
• Phone: 2059346504
• Email: ariddle@uabmc.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: April 20, 2018
• Completion date: April 1, 2026